Last reviewed · How we verify
Neoadjuvant immunochemotherapy
Neoadjuvant immunochemotherapy combines chemotherapy with immunotherapy agents to enhance anti-tumor immune responses before surgical resection.
Neoadjuvant immunochemotherapy combines chemotherapy with immunotherapy agents to enhance anti-tumor immune responses before surgical resection. Used for Resectable or locally advanced solid tumors (specific tumor type not specified in available data).
At a glance
| Generic name | Neoadjuvant immunochemotherapy |
|---|---|
| Also known as | Neoadjuvant immunotherapy, surgery |
| Sponsor | Henan Cancer Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This treatment approach uses chemotherapy to reduce tumor burden and promote immunogenic cell death, while simultaneously activating the immune system through checkpoint inhibitors or other immunotherapeutic agents. Administered before surgery (neoadjuvant setting), it aims to improve pathological complete response rates and enhance long-term survival by priming anti-tumor immunity before definitive surgical intervention.
Approved indications
- Resectable or locally advanced solid tumors (specific tumor type not specified in available data)
Common side effects
- Chemotherapy-related myelosuppression
- Immune-related adverse events (fatigue, rash, pneumonitis)
- Gastrointestinal toxicity
- Cardiac toxicity
Key clinical trials
- Development and Multicenter Validation of a Novel Bio-Anatomical Staging System for Predicting Survival and Tailoring Adjuvant Therapy in ESCC After Neoadjuvant Chemoimmunotherapy.
- Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma (PHASE2)
- Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
- Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (PHASE2)
- Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer
- Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer (PHASE2)
- Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma (PHASE2)
- Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant immunochemotherapy CI brief — competitive landscape report
- Neoadjuvant immunochemotherapy updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI